Streetbeat News

Regulatory

NBTX

Nanobiotix has announced the final efficacy analysis from its Phase 1 cohort expansion evaluating NBTXR3 in locally advanced head and neck cancer. The results show a median progression-free survival of 16.9 months and median overall survival of 23.1 months. The study found that NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity. Compared with historical data, these results potentially strengthen the hypothesis and clarify next steps for the ongoing global, Phase 3 study evaluating NBTXR3.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:34 pm

HPLT

Home Plate Acquisition Corporation (NASDAQ:HPLT) has cancelled its special meeting of stockholders and announced its intention to dissolve and liquidate. The company will redeem all outstanding shares of Class A common stock at an estimated per-share redemption price of $10.52. The company's securities are expected to be delisted from NASDAQ. Heidmar Inc. intends to terminate the Business Combination Agreement with Home Plate.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:27 pm

AYRO

Ayro Inc has regained compliance with the minimum bid price requirement of Nasdaq, as per the notice received from Nasdaq on October 2.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:26 pm

ABBV

AbbVie has reported its GAAP earnings for Q3, which are expected to include an acquired IPR&D and milestones expense of $66M on a pre-tax basis, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:15 pm

IMRX

Immuneering Corporation will present preclinical data on IMM-1-104 and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:14 pm

VCYT

Veracyte, Inc. (NASDAQ:VCYT) announced new data from a phase 3 trial that reinforces the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer. The findings were presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting. A second study presented at the meeting revealed minimal to moderate risk-score correlation between three commercially available genomic classifiers, suggesting that the level of evidence supporting each genomic test should drive utilization.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:12 pm

GRTS

Gritstone Bio has announced presentations from Phase 1 studies evaluating its next-generation vaccine candidate for COVID-19 at IDWeek 2023.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:10 pm

ASLE

BA

AerSale is nearing the conclusion of the FAA certification process for its enhanced flight vision system, AerAware, which is applicable to the Boeing 737NG and MAX aircraft.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 8:09 pm

BYSI

BeyondSpring has received a notice from Nasdaq regarding its failure to meet the minimum bid price requirements. The company's shares have been trading below $1.00, which is the minimum bid price requirement for continued listing on the Nasdaq Stock Market.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 7:59 pm

BTCUSD

Despite the arrest of FTX co-founder Sam Bankman-Fried and the collapse of his cryptocurrency exchange FTX, Bitcoin's price has rallied over 60%. The downfall of FTX was due to unsustainable layers of deception, including the disappearance of $1 billion in customer funds. Despite these setbacks, investor support for Bitcoin remains strong. Crypto services provider Matrixport estimates Bitcoin to peak at $37,000 by the end of the year.

Portfolio Pulse from Khyathi Dalal

October 04, 2023 | 7:37 pm